



# BD BioGX SARS-CoV-2 Reagents for BD MAX™ System

REF 444213

For Emergency Use Authorization (EUA) Only  
For *In Vitro* Diagnostic Use  
For use with the BD MAX™ System

P0251(04)  
2020-05  
English



R<sub>x</sub> Only

## INTENDED USE

The BioGX SARS-CoV-2 Reagents for BD MAX™ System is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal, nasal, mid-turbinate, and oropharyngeal swab specimens, nasopharyngeal wash/aspirate or nasal aspirates obtained from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate and high complexity tests.

Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

The BioGX SARS-CoV-2 Reagents for BD MAX System is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR, *in vitro* diagnostic procedures, and use of the BD MAX System. The BioGX SARS-CoV-2 Reagents for BD MAX System is only for use under the Food and Drug Administration's Emergency Use Authorization.

## EXPLANATION OF THE TEST

Total nucleic acid (TNA) is isolated and purified using BD MAX™ ExK™ TNA-3 kit from nasopharyngeal and/or oropharyngeal swabs collected in BD Universal Viral Transport System (UVT) or Copan Universal Transport Media System (UTM). Patient sample is transferred to the Sample Buffer Tube (SBT) provided with the BD MAX ExK TNA-3 kit and placed in the BD MAX System. The final eluate is used to rehydrate BioGX SARS-CoV-2 Reagents, which contains all reagents necessary for RT-PCR including primers and probes. This rehydrated master mix is subsequently transferred to a BD MAX PCR cartridge.

The BD SARS-CoV-2 Reagents for BD MAX System utilizes multiplexed primers and probes targeting RNA from the nucleocapsid phosphoprotein gene (N1 and N2 regions) of the SARS-CoV-2 coronavirus, and the human RNase P gene. The primer and probe sets are based on the United States Centers for Disease Control and Prevention (US CDC) assay for specific detection of SARS-CoV-2 by amplifying two unique regions of the N gene (i.e., N1 and N2).

An internal control targeting the human RNase P gene will be co-amplified along with N1 and N2 gene targets (if present) and will serve as an endogenous nucleic acid extraction control present in all properly collected patient samples. This control serves as both an extraction control and an internal amplification control.

## PRINCIPLES OF THE PROCEDURE

A combination of lytic and extraction reagents is used to perform cell lysis and DNA/RNA extraction. Nucleic acids released from the target organisms are captured on magnetic affinity beads. The beads, together with the bound nucleic acids, are washed and the nucleic acids are eluted by a combination of heat and pH variation. The final eluate is used to rehydrate BioGX SARS-CoV-2 Reagents, which contains all reagents necessary for RT-PCR including primers and probes. After reconstitution, the BD MAX System dispenses a fixed volume of RT-PCR-ready solution containing extracted nucleic acids into the PCR Cartridge. Microvalves on the cartridge are sealed by the system prior to initiating PCR in order to contain the amplification mixture and thus prevent evaporation and contamination.

The amplified cDNA targets are detected using hydrolysis (TaqMan®) probes, labeled at one end with a fluorescent reporter dye (fluorophore), and at the other end, with a quencher moiety. Probes labeled with different fluorophores are used to detect the target analytes in different optical channels of the BD MAX System. When the probes are in their native state, the fluorescence of the fluorophore is quenched due to its proximity to the quencher. However, in the presence of target cDNA, the probes hybridize to their complementary sequences and are hydrolyzed by the 5'–3' exonuclease activity of the DNA polymerase as it synthesizes the nascent strand along the cDNA template. As a result, the fluorophores are separated from the quencher molecules and fluorescence is emitted. The amount of fluorescence detected in the optical channels is directly proportional to the quantity of the corresponding probe that is hydrolyzed. The BD MAX System monitors these signals at each cycle of the PCR and interprets the data at the end of the reaction to provide qualitative test results for each analyte.

## REAGENTS AND MATERIALS

REF	CONTENTS	QUANTITY
444213	<b>BioGX SARS-CoV-2 Reagents for BD MAX System</b> Lyophilized reagents for multiplexed detection of N1 and RNase P. Each tube is sufficient for a 12.5 µL reaction, sealed in BD MAX 0.3 mL conical tubes	24 tests
	<b>BioGX SARS-CoV-2 Reagents for BD MAX System</b> Lyophilized reagents for multiplexed detection of N2 and RNase P. Each tube is sufficient for a 12.5 µL reaction, sealed in BD MAX 0.3 mL conical tubes	24 tests
	<b>BioGX Rehydration Buffer</b> Sealed in BD MAX 0.3 mL conical tubes. Each tube contains 25 µL of buffer	24 tests

## EQUIPMENT AND MATERIALS REQUIRED BUT NOT PROVIDED

- BD MAX System (BD Cat. No. 441916)
- BD MAX Sample Rack (BD Cat. No. 441935, 443550, 443551, 444807, or 444808)
- BD MAX ExK TNA-3 (BD Cat. No. 442827)
- BD MAX PCR Cartridges (BD Cat. No. 437519)
- SARS-CoV-2 Controls
- Copan UTM Collection Kit
- BD UVT Collection Kit
- Vortex Genie 2 (VWR Cat. No. 58815-235 or equivalent)
- Multi-Tube Vortex Mixer (VWR Cat. No. 58816-115 or equivalent)
- Rack compatible with a multi-tube vortexer (e.g., Cryogenic Vial Holder or equivalent)
- Variable Volume Calibrated Pipettor (750 µL volume capable)
- Aerosol resistant micropipette tips
- Disposable gloves, powderless

## WARNINGS AND PRECAUTIONS

- For *in vitro* diagnostic use under Emergency Use Authorization only.
- For Prescription Use only.
- Positive results are indicative of the presence of SARS-CoV-2 RNA.
- Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.
- All patient samples should be handled as if infectious, using good laboratory procedures as outlined in the CLSI Document M29-A4<sup>1</sup> and in Biosafety in Microbiological and Biomedical Laboratories.<sup>2</sup> Only personnel proficient in handling infectious materials and the use of BioGX SARS-CoV-2 and BD MAX System should perform this procedure.
- All human-sourced materials should be considered potentially infectious and should be handled with universal precautions. If spillage occurs, follow appropriate site procedures.
- Closely follow procedures and guidelines provided to ensure that the test is performed correctly. Any deviation from the procedures and guidelines may affect optimal test performance.
- Do not use expired reagents and/or materials.
- Do not use the kit if the label that seals the outer box is broken upon arrival.
- Do not use reagents if the protective pouches are open or broken upon arrival.
- Do not use reagents if desiccant is not present or broken inside reagent pouches.
- Do not remove desiccant from reagent pouches.
- Close protective pouches of reagents promptly with the zip seal after each use. Remove any excess air in the pouches prior to sealing.
- Protect reagents against heat and humidity. Prolonged exposure to humidity may affect product performance.
- Do not use reagents if the foil has been broken or damaged.
- Do not mix reagents from different pouches and/or kits and/or lots.
- Do not interchange or re-use caps, as contamination may occur and compromise test results.

- Check Unitized Reagent Strips for proper liquid fills (ensure that the liquids are at the bottom of the tubes).
- Check Unitized Reagent Strips to ensure that all pipette tips are present.
- Proceed with caution when using chemical solutions, as Extraction Tube barcode readability may be altered.
- Good laboratory technique is essential to the proper performance of this assay. Extreme care should be taken to preserve the purity of all materials and reagents.
- In cases where other PCR tests are conducted in the same general area of the laboratory, care must be taken to ensure that the BD MAX ExK TNA-3 components, any additional reagents required for testing, and the BD MAX System are not contaminated. Avoid microbial and ribonuclease (RNase)/deoxyribonuclease (DNase) contamination of reagents at all times. The use of sterile RNase/DNase-free disposable aerosol resistant or positive displacement pipette tips is recommended. Use a new tip for each specimen. Gloves must be changed before manipulating reagents and cartridges.
- To avoid contamination of the environment by amplicons, do not break apart the BD MAX PCR Cartridge after use. The seals of the BD MAX PCR Cartridges are designed to prevent contamination.
- The laboratory should routinely perform environmental monitoring to minimize the risk of cross-contamination.
- Wear protective clothing and disposable gloves while handling all reagents.
- Wash hands thoroughly after performing the test.
- Do not pipette by mouth.
- Do not smoke, drink, chew or eat in areas where specimens or kit reagents are being handled.
- Dispose of unused reagents and waste in accordance with local, state, provincial and/or federal regulations.
- Consult the BD MAX System User's Manual<sup>3</sup> for additional warnings, precautions, and procedures.

## STORAGE AND STABILITY

### BioGX SARS-CoV-2 Reagents for BD MAX System

BioGX SARS-CoV-2 Reagents for BD MAX System components are provided in sealed pouches and ships at ambient temperature. To protect the product from humidity, immediately re-seal after opening. Open pouch stability for similar products has been established for 1 month at ambient temperature and closed pouch for 6 months at ambient temperature.

## INSTRUCTIONS FOR USE

### Swab Specimen Collection/Transport

**Note: Wear gloves when handling Universal Viral Transport (UVT) or Universal Transport Media (UTM) specimens. If gloves come in contact with the specimen, immediately change them to prevent contamination of other specimens.**

1. Nasopharyngeal / oropharyngeal swab specimens should be collected and expressed directly into the BD Universal Viral Transport System or the Copan Universal Transport Media System according to their respective package insert instructions.
2. Transport the UVT/UTM specimen according to the manufacturer's instructions for use.

### BD MAX Sample Buffer Tube Preparation

**Note: Wear gloves when handling Universal Viral Transport (UVT) or Universal Transport Media (UTM) specimens. If gloves come in contact with the specimen, immediately change them to prevent contamination of other specimens.**

**Note: If frozen, allow Universal Transport Media (UTM) specimen to come to room temperature before proceeding.**

1. Uncap the BD MAX TNA-3 Sample Buffer Tube and transfer (using a calibrated, variable pipette) 750 µL from the UVT/UTM specimen directly into the BD MAX TNA-3 Sample Buffer Tube.
2. Recap the tube with a blue septum cap and vortex or mix by inversion 5 times.
3. Label the BD MAX TNA-3 Sample Buffer Tube with patient information.

**Note: Do not obscure the barcodes on the tube. Obscuring the barcode may result in BD MAX System catalog failure and inability to test the sample.**


4. Repeat Steps 1 to 3 for each UVT/UTM sample that will be tested on the BD MAX System.
5. Proceed directly with the BD MAX System Operation.

### BD MAX System Operation

**Note: Refer to the BD MAX System User's Manual<sup>3</sup> for detailed instructions (Operation section).**

1. Power on the BD MAX System (if not already done) and log in by entering <user name> and <password>.
2. Gloves must be changed before manipulating reagents and cartridges.
3. Remove the required number of Unitized Reagent Strips from the BD MAX ExK TNA-3 kit. Gently tap each Unitized Reagent Strip onto a hard surface to ensure that all the liquids are at the bottom of the tubes. Remove the required number of Extraction Tube(s) from the protective pouch. Remove excess air, and close pouch with the zip seal.
4. From the BioGx SARS-CoV-2 kit, remove the required number of Master Mix Tube(s) and rehydration buffer tubes from the protective pouches. Remove excess air, and close pouch with the zip seal.

- For each specimen to be tested, place one (1) Unitized Reagent Strip on the BD MAX System Rack. Assemble the strip as in Figure 1:



**Figure 1:** Snap Extraction Tubes and Master Mix Tubes into Unitized Reagent Strips

**Note:** Failure to add extraction tube and master mix tubes may result in instrument contamination.

**Note:** A conical snap-in tube is fully seated in the strip when a 'click' is heard. Refer to above for reagent placement in the Unitized Reagent Strip.

- Position 1= Snap the BD MAX TNA-3 Extraction Tube into Position 1.
  - Position 2= Snap the BioGX "N1, RNaseP" lyophilized master mix into Position 2.
  - Position 3= Snap the BioGX Rehydration Buffer tube into Position 3.
  - Position 4= Snap the BioGX "N2, RNaseP" lyophilized master mix into Position 4.
- Create the User Defined Protocol (UDP) as follows:
    - Navigate to Run > Test Editor tab.
    - Click "Create".
    - Complete each section of the user protocol as outlined in the screen shots below.

#### Basic Information Section

Run > Test Editor > Edit > Basic Information

Test Name: 350093CMAK Extraction Type: ExK TNA-3 Master Mix Format: Dual Master Mix: Lyophilized MM with Rehydration Buffer (Type 4)

Sample Extraction Parameters

Parameter	Value	Default	Value Range
Lysis Heat Time	10	10	0 - 30 ± 1 mins
Lysis Temperature	60	60	30 - 80 ± 1 °C
Sample Tip Height	1600	1600	1200 - 1600 ± 1 steps
Sample Volume	600	937.5	250 - 950 ± 2.5 µL
Wash Volume	500	500	187.5 - 500 ± 2.5 µL
Neutralization Volume	--	--	--
DNase Heat Time	--	--	--

Ct Calculation

☐ Call Ct at Inflection Point

☐ Call Ct at Threshold Crossing

☒ Call Ct at Threshold Crossing with Secondary QC Threshold

Custom Barcodes

Snap-In 2 Barcode: Snap-In 3 Barcode: Snap-In 4 Barcode:

Notes

0/255 characters used

Save Cancel

Back to Test List

Worklist PCR Only Test Editor Inventory

Run Status Results Configuration Reports Maintenance

## PCR Setting Section Snap2

Run > Test Editor > Edit > PCR Settings: Snap-In 2 (green)

Test Name: 350093CMAX Extraction Type: ExK TNA-3 Master Mix Format: Dual Master Mix: Lyophilized MM with Rehydration Buffer (Type 4)

PCR Settings

Channel	Wavelength	Alias	PCR Gain	Threshold (Cross)	Ct Min	Ct Max
Channel	475/520	CoV N1	80	150	0	42
	530/565		0	0	0	0
	585/630		0	0	0	0
	630/665		0	0	0	0
	680/715	RNase P	60	100	0	35

Color Compensation

Excitation Channel	Wavelength	475/520	530/565	585/630	630/665	680/715
Excitation Channel	475/520	--	0	0	0	0
	530/565	0	--	0	0	0
	585/630	0	0	--	0	0
	630/665	0	0	0	--	0
	680/715	0	0	0	0	--

Save Cancel

Worklist PCR Only Test Editor Inventory

Run Status Results Configuration Reports Maintenance

Log Out Unlock Door Start

3/18/2020 8:39:40 AM Instrument: 1 User: ADMIN

Basic Information

PCR Settings: Snap-In 2 (green)

Melt Settings: Snap-In 2 (green)

Test Steps: Snap-In 2 (green)

PCR Settings: Snap-In 4 (blue)

Melt Settings: Snap-In 4 (blue)

Test Steps: Snap-In 4 (blue)

Result Logic

Back to Test List

## Melt Settings Section Snap2

Run > Test Editor > Edit > Melt Settings: Snap-In 2 (green)

Test Name: 350093CMAX Extraction Type: ExK TNA-3 Master Mix Format: Dual Master Mix: Lyophilized MM with Rehydration Buffer (Type 4)

Melt Settings

Channel	Wavelength	Alias	Melt Gain	Peak Direction	Sensitivity	Melt Bins
Channel	475/520	CoV N1	0	Peak	Medium	Edit Melt Bins
	530/565		0	Peak	Medium	Edit Melt Bins
	585/630		0	Peak	Medium	Edit Melt Bins
	630/665		0	Peak	Medium	Edit Melt Bins
	680/715	RNase P	0	Peak	Medium	Edit Melt Bins

Color Compensation

Excitation Channel	Wavelength	475/520	530/565	585/630	630/665	680/715
Excitation Channel	475/520	--	0	0	0	0
	530/565	0	--	0	0	0
	585/630	0	0	--	0	0
	630/665	0	0	0	--	0
	680/715	0	0	0	0	--

Save Cancel

Worklist PCR Only Test Editor Inventory

Run Status Results Configuration Reports Maintenance

Log Out Unlock Door Start

3/18/2020 8:39:42 AM Instrument: 1 User: ADMIN

Basic Information

PCR Settings: Snap-In 2 (green)

Melt Settings: Snap-In 2 (green)

Test Steps: Snap-In 2 (green)

PCR Settings: Snap-In 4 (blue)

Melt Settings: Snap-In 4 (blue)

Test Steps: Snap-In 4 (blue)

Result Logic

Back to Test List

## Test Steps Section Snap2

Run > Test Editor > Edit > Test Steps: Snap-In 2 (green)

Test Name: 350093CMAX Extraction Type: ExK TNA-3 Master Mix Format: Dual Master Mix: Lyophilized MM with Rehydration Buffer (Type 4)

Test Steps

Step Name: RT

Profile Type: Hold Cycles: 1

Type	Time (s)	Temp (°C)	Detect
	900	43	

Move Add

Step Name: Denaturation

Profile Type: Hold Cycles: 1

Type	Time (s)	Temp (°C)	Detect
	120	99	

Move Add

Step Name: PCR

Profile Type: 3 - Temperature Cycles: 45

Type	Time (s)	Temp (°C)	Detect
	5	99	
	16	60	
	25.6	72	<input checked="" type="checkbox"/>

Move Add

Save Cancel

Worklist PCR Only Test Editor Inventory

BD Log Out Unlock Door Start Run Status Results Configuration Reports Maintenance

Basic Information

PCR Settings: Snap-In 2 (green)

Melt Settings: Snap-In 2 (green)

Test Steps: Snap-In 2 (green)

PCR Settings: Snap-In 4 (blue)

Melt Settings: Snap-In 4 (blue)

Test Steps: Snap-In 4 (blue)

Result Logic

Back to Test List

## PCR Setting Section Snap4

Run > Test Editor > Edit > PCR Settings: Snap-In 4 (blue)

Test Name: 350093CMAX Extraction Type: ExK TNA-3 Master Mix Format: Dual Master Mix: Lyophilized MM with Rehydration Buffer (Type 4)

PCR Settings

Wavelength	Alias	PCR Gain	Threshold (Cross)	Ct Min	Ct Max
475/520	CoV N2	80	150	0	42
530/565		0	0	0	0
585/630		0	0	0	0
630/665		0	0	0	0
680/715	RNase P	60	100	0	35

Color Compensation

Wavelength	475/520	530/565	585/630	630/665	680/715
475/520	--	0	0	0	0
530/565	0	--	0	0	0
585/630	0	0	--	0	0
630/665	0	0	0	--	0
680/715	0	0	0	0	--

Save Cancel

Worklist PCR Only Test Editor Inventory

BD Log Out Unlock Door Start Run Status Results Configuration Reports Maintenance

Basic Information

PCR Settings: Snap-In 2 (green)

Melt Settings: Snap-In 2 (green)

Test Steps: Snap-In 2 (green)

PCR Settings: Snap-In 4 (blue)

Melt Settings: Snap-In 4 (blue)

Test Steps: Snap-In 4 (blue)

Result Logic

Back to Test List

## Melt Settings Section Snap4

Run > Test Editor > Edit > Melt Settings: Snap-In 4 (blue)

Test Name: 350093CMAX Extraction Type: ExK TNA-3 Master Mix Format: Dual Master Mix: Lyophilized MM with Rehydration Buffer (Type 4)

**Melt Settings**

Channel	Wavelength	Alias	Melt Gain	Peak Direction	Sensitivity	Melt Bins
Channel	475/520	CoV N2	- 0 +	Peak	Medium	Edit Melt Bins
	530/565		- 0 +	Peak	Medium	Edit Melt Bins
	585/630		- 0 +	Peak	Medium	Edit Melt Bins
	630/665		- 0 +	Peak	Medium	Edit Melt Bins
	680/715	RNase P	- 0 +	Peak	Medium	Edit Melt Bins

**Color Compensation**

Excitation Channel	Wavelength	475/520	530/565	585/630	630/665	680/715
Excitation Channel	475/520	--	- 0 +	- 0 +	- 0 +	- 0 +
	530/565	- 0 +	--	- 0 +	- 0 +	- 0 +
	585/630	- 0 +	- 0 +	--	- 0 +	- 0 +
	630/665	- 0 +	- 0 +	- 0 +	--	- 0 +
	680/715	- 0 +	- 0 +	- 0 +	- 0 +	--

Save Cancel

Worklist PCR Only Test Editor Inventory

BD Log Out Unlock Door Start Run Status Results Configuration Reports Maintenance

Basic Information  
PCR Settings: Snap-In 2 (green)  
Melt Settings: Snap-In 2 (green)  
Test Steps: Snap-In 2 (green)  
PCR Settings: Snap-In 4 (blue)  
Melt Settings: Snap-In 4 (blue)  
Test Steps: Snap-In 4 (blue)  
Result Logic  
Back to Test List

## PCR Setting Section Snap4

Run > Test Editor > Edit > Test Steps: Snap-In 4 (blue)

Test Name: 350093CMAX Extraction Type: ExK TNA-3 Master Mix Format: Dual Master Mix: Lyophilized MM with Rehydration Buffer (Type 4)

**Test Steps**

Step Name: RT

Profile Type: Hold Cycles: 1

Type	Time (s)	Temp (°C)	Detect
	900	43	

Move Add

Step Name: Denaturation

Profile Type: Hold Cycles: 1

Type	Time (s)	Temp (°C)	Detect
	120	99	

Move Add

Step Name: PCR

Profile Type: 3 - Temperature Cycles: 45

Type	Time (s)	Temp (°C)	Detect
	5	99	
	16	60	
	25.6	72	✓

Move Add

Save Cancel

Worklist PCR Only Test Editor Inventory

BD Log Out Unlock Door Start Run Status Results Configuration Reports Maintenance

Basic Information  
PCR Settings: Snap-In 2 (green)  
Melt Settings: Snap-In 2 (green)  
Test Steps: Snap-In 2 (green)  
PCR Settings: Snap-In 4 (blue)  
Melt Settings: Snap-In 4 (blue)  
Test Steps: Snap-In 4 (blue)  
Result Logic  
Back to Test List

## Result Logic Section

Run > Test Editor > Edit > Result Logic

Test Name: 350093CMAX Extraction Type: ExK TNA-3 Master Mix Format: Dual Master Mix: Lyophilized MM with Rehydration Buffer (Type 4)

Result Logic Steps

Target: CoV N1

Master Mix: Snap-In 2 (green)

Wavelength	Alias	Type	Analyze
475/520	CoV N1	PCR	<input checked="" type="checkbox"/>
680/715	RNase P	PCR	<input checked="" type="checkbox"/>

Edit Logic

Move Add

Target: CoV N2

Master Mix: Snap-In 4 (blue)

Wavelength	Alias	Type	Analyze
475/520	CoV N2	PCR	<input checked="" type="checkbox"/>
680/715	RNase P	PCR	<input checked="" type="checkbox"/>

Edit Logic

Move Add

Target: RNaseP1

Master Mix: Snap-In 2 (green)

Wavelength	Alias	Type	Analyze
680/715	RNase P	PCR	<input checked="" type="checkbox"/>
475/520	CoV N1	PCR	<input type="checkbox"/>

Edit Logic

Move Add

Save Cancel

Worklist PCR Only Test Editor Inventory

Log Out Unlock Door Run Status Results Configuration Reports Maintenance

Edit Logic

Target: CoV N1

Result	CoV N1 (475/520) PCR	RNase P (680/715) PCR
POS	Valid	Valid
POS	Valid	Invalid
NEG	Invalid	Valid
UNR	Invalid	Invalid

OK

Edit Logic

Target: CoV N2

Result	CoV N2 (475/520) PCR	RNase P (680/715) PCR
POS	Valid	Valid
POS	Valid	Invalid
NEG	Invalid	Valid
UNR	Invalid	Invalid

OK

Edit Logic

Target: RNaseP1

Result	RNase P (680/715) PCR
POS	Valid
NEG	Invalid

OK

Run > Test Editor > Edit > Result Logic

Test Name: 350093CMAX Extraction Type: ExK TNA-3 Master Mix Format: Dual Master Mix: Lyophilized MM with Rehydration Buffer (Type 4)

Result Logic Steps

Target: CoV N2

Master Mix: Snap-In 4 (blue)

Wavelength	Alias	Type	Analyze
475/520	CoV N2	PCR	<input checked="" type="checkbox"/>
680/715	RNase P	PCR	<input checked="" type="checkbox"/>

Edit Logic

Move Add

Target: RNaseP1

Master Mix: Snap-In 2 (green)

Wavelength	Alias	Type	Analyze
680/715	RNase P	PCR	<input checked="" type="checkbox"/>
475/520	CoV N1	PCR	<input type="checkbox"/>

Edit Logic

Move Add

Target: RNaseP2

Master Mix: Snap-In 4 (blue)

Wavelength	Alias	Type	Analyze
680/715	RNase P	PCR	<input checked="" type="checkbox"/>
475/520	CoV N2	PCR	<input type="checkbox"/>

Edit Logic

Move Add

Save Cancel

Worklist PCR Only Test Editor Inventory

Log Out Unlock Door Run Status Results Configuration Reports Maintenance

Edit Logic

Target: RNaseP2

Result	RNase P (680/715) PCR
POS	Valid
NEG	Invalid

OK

Note: Click on the scroll bar to scroll right.



7. Click **<SAVE>** after all information has been entered into the Test Editor. The UDP only needs to be created once, and steps 6 and 7 do not need to be repeated for subsequent runs.
8. Click on the Run tab, then Inventory. Enter the kit lot number for the BD MAX ExK TNA-3 (for lot traceability) by either scanning the barcode with the scanner or by manual entry and then save.


**Note: Repeat step 8 each time a new kit lot is used.**

9. Navigate to the Worklist (RUN > WORKLIST). Using the pull down menu select the UDP previously created in Step 6 (example: 350093CMAX).
10. Enter the Sample Buffer Tube ID, Patient ID and Accession Number (if applicable) into the Worklist, either by scanning the barcode with the scanner or by manual entry.
11. Select the appropriate kit lot number (found on the outer box) from the pull down menu.
12. Repeat Steps 9 to 11 for all remaining Sample Buffer Tubes.
13. Place the Sample Buffer Tubes into the BD MAX System Rack(s) corresponding to the Unitized Reagent Strips previously assembled.
14. Place the required number of BD MAX PCR Cartridge(s) into the BD MAX System (refer to Figure 2).



**Figure 2:** Load BD PCR Cartridges

15. Load rack(s) onto the BD MAX System (refer to Figure 3).



**Figure 3:** Load Rack(s) onto the BD MAX System

16. Close the BD MAX System lid and click **<Start>** to begin the processing.

## QUALITY CONTROL

Quality control procedures monitor the performance of the assay. Laboratories must establish the number, type, and frequency of testing of control materials according to guidelines or requirements of local, provincial, state, and federal and/or country regulations or accreditation organizations in order to monitor the effectiveness of the entire analytical process. For general Quality Control guidance, the user may wish to refer to CLSI MM3 and EP12.<sup>1,2</sup>

External Control materials are not provided by BD. External Positive and Negative Controls are not used by the BD MAX System software for the purpose of sample test result interpretation. External Controls are treated as if they were patient samples. (Refer to the table in the Results Interpretation section for the interpretation of External Control assay results.)

It is recommended that one (1) External Positive Control and one (1) External Negative Control be run at least daily until adequate process validation is achieved on the BD MAX System in each laboratory setting. All test controls should be examined prior to interpretation of patient results. If controls are not valid, the patient results cannot be interpreted. Reduced frequency of control testing should be in accordance with applicable regulations.

The External Positive Control is intended to monitor for substantial reagent failure. The External Negative Control is intended to detect reagent or environmental contamination (or carry-over) by target nucleic acids.

Various types of External Controls are recommended to allow the user to select the most appropriate for their laboratory quality control program.

**External Negative Control:** A previously characterized sample known to be negative or an SBT with RNase P external control added. BD recommends that the External Negative Control be prepared prior to the External Positive Control in order to reduce the potential for contamination as a result of control preparation.

**External Positive Control:** Commercially available control material from BioGX or other authorized control material may be used. For the preparation of External Control suspensions, it is recommended that RNA suspensions be prepared in the Sample Buffer Tube (SBT) according to manufacturer's instructions.

All External Controls should yield the expected results (positive for External Positive Control, negative for External Negative Control).

An External Negative Control that yields a positive result is indicative of sample handling and/or contamination. An External Positive Control that yields a negative result is indicative of a specimen handling/preparation problem. Review the specimen handling/preparation technique.

An External Control that yields an Unresolved, Indeterminate or Incomplete test result is indicative of a reagent or a BD MAX System failure. Check the BD MAX System monitor for any error messages. Refer to the System Error Summary section of the BD MAX System User's Manual<sup>3</sup> for interpretation of warning and error codes. If the problem persists, use reagents from an unopened pouch or use a new assay kit.

## RESULT INTERPRETATION

Results are available on the results tab in the Results window on the BD MAX System monitor. The BD MAX System automatically interprets the test result when the SARS-CoV-2 User Defined Protocol (UDP) is used.

### External Negative and Positive Controls

If the positive or negative controls are processed in the run and do not exhibit the expected performance as described in the Control Interpretations table below, the assay may have been set up/or executed improperly, or reagent or equipment malfunction could have occurred. In this case, invalidate the run and re-test all samples in that run.

The RNase P gene serves as both a sample extraction control (EC) and an internal amplification control (IAC). In the event that both N1 and N2 region results are negative, an RNase P result must be positive for the BD BioGX SARS-CoV-2 result to be a valid negative result. When either N1 or N2 target result is positive, the RNase P result is ignored.

If any of the above controls do not exhibit the expected performance as described, the assay may have been set up/or executed improperly, or reagent or equipment malfunction could have occurred. Invalidate the run and re-test.

**Table 1: External Control Interpretations**

Control Type		Used to Monitor	Expected Results			
			BioGX “N1, RNase P” master mix		BioGX “N2, RNase P” master mix	
			N1	RNase P	N2	RNase P
<b>External Negative Control</b>	Known Negative Sample	Reagent and/or environmental contamination and reagent failure including primer and probe integrity	NEG	POS	NEG	POS
	RNase P Positive Control					
<b>External Positive Control</b>	N1 and N2 Positive Control	Substantial reagent failure including primer and probe integrity	POS	NEG	POS	NEG

### Examination and Interpretation of Patient Specimen Results

Assessment of clinical specimen test results should be performed after the external positive and negative controls have been examined and determined to be valid and acceptable. If the controls are not valid, the patient results cannot be interpreted.

The table below lists the expected results. If results are obtained that do not follow these guidelines, re-extract and re-test the sample. If repeat testing yields similar results, collect a fresh sample from the patient for testing.

**Table 2: Interpretation of Patient Specimen Results**

BioGX “N1, RNase P” master mix		BioGX “N2, RNase P” master mix		Result Interpretation <sup>a,b</sup>	Actions
N1 Target	RNase P	N2 Target	RNase P		
+	+/-	+	+/-	Positive	Report as Positive
+	+/-	-	+	Positive	Report as Positive
+	+/-	UNR	-	Positive	Report as Positive
-	+	+	+/-	Positive	Report as Positive
UNR	-	+	+/-	Positive	Report as Positive
UNR	-	-	+	UNR	Repeat Test <sup>c</sup>
-	+	UNR	-	UNR	Repeat Test <sup>c</sup>
UNR	-	UNR	-	UNR	Repeat Test <sup>c</sup>
-	+	-	+	Negative	Report as Negative

<sup>a</sup> In the absence of target detection in each of the master mix reactions, the external control (RNase P) must be detected in that master mix reaction in order for the result to be valid.

<sup>b</sup> Laboratories should report their diagnostic result as appropriate and in compliance with their specific reporting system. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.

<sup>c</sup> Repeat Test by preparing a fresh sample buffer tube from the original primary UVT or UTM sample.

### UNRESOLVED, INDETERMINATE, AND INCOMPLETE RESULTS

When an Indeterminate (IND), Unresolved (UNR), or Incomplete (INC) result is obtained a repeat test from the Patient Sample must be performed (see Repeat Test Procedure). If an External Control fails, repeat testing of all specimens conducted on the same day using freshly prepared External Controls (see Quality Control).

#### Unresolved Result

Unresolved results may be obtained in the event that specimen-associated inhibition or reagent failure prevents proper target or RNase P amplification. Sample(s) can be repeated from the original Patient Sample. Uncap the BD MAX TNA-3 Sample Buffer Tube and transfer (using a calibrated, variable pipette) 750 µL from the UVT/UTM specimen directly into the BD MAX TNA-3 Sample Buffer Tube. Restart from the BD MAX System Operation section.

#### Indeterminate Result

Indeterminate results may be obtained in the event that a System failure occurs. Sample(s) can be repeated from the original Patient Sample. Uncap the BD MAX TNA-3 Sample Buffer Tube and transfer (using a calibrated, variable pipette) 750 µL from the UVT/UTM specimen directly into the BD MAX TNA-3 Sample Buffer Tube. Restart from the BD MAX System Operation section.

#### Incomplete Result

Incomplete results may be obtained in the event that Specimen Preparation or the PCR did not reach its expected time points. Sample(s) can be repeated from the original Patient Sample. Uncap the BD MAX TNA-3 Sample Buffer Tube and transfer (using a calibrated, variable pipette) 750 µL from the UVT/UTM specimen directly into the BD MAX TNA-3 Sample Buffer Tube. Restart from the BD MAX System Operation section.

### External Control Failure

External Controls should yield expected results when tested. If samples have to be repeated due to an incorrect External Control result, the samples should be repeated from the original Patient Sample along with freshly prepared External Controls. Restart from the BD MAX System Operation section.

### LIMITATIONS OF THE PROCEDURE

- BioGX SARS-CoV-2 Reagents for BD MAX System has been evaluated only for use in combination with the BD MAX TNA-3 kit and BD MAX System.
- Reliable results depend on proper sample collection, storage and handling procedures.
- This test is intended to be used for the detection of SARS-CoV-2 RNA in nasopharyngeal and oropharyngeal swab samples collected in BD Universal Viral Transport System (UVT) or Copan Universal Transport Media System (UTM). Testing of other sample types may result in inaccurate results.
- Nasopharyngeal wash/aspirates, nasal aspirates, and nasal/mid-turbinate nasal swabs (self-collected under supervision of a healthcare provider or healthcare provider-collected) are additional acceptable upper respiratory specimens that can be tested with BioGX SARS-CoV-2 Reagents for BD MAX System; however, performance with these specimen types have not been determined.
- Detection of SARS-CoV-2 RNA may be affected by sample collection methods, patient factors (e.g., presence of symptoms), and/or stage of infection.
- As with any molecular test, mutations within the target regions of SARS-CoV-2 could affect primer and/or probe binding resulting in failure to detect the presence of virus.
- Due to inherent differences between technologies, it is recommended that, prior to switching from one technology to the next, users perform method correlation studies in their laboratory to qualify technology differences. One hundred percent agreement between the results should not be expected due to aforementioned differences between technologies. Users should follow their own specific policies/procedures.
- False negative or invalid results may occur due to interference. The RNase P endogenous control is included to help identify the specimens containing substances that may interfere with nucleic acid isolation and PCR amplification.
- Good laboratory practices and careful adherence to the procedures specified in this Instructions For Use document are necessary to avoid contamination of reagents.
- For the BD MAX TNA extraction: Tobramycin at  $1.1 \times 10^{-3}$  g/SBT interferes with the assay. Lower concentrations of Tobramycin have not been evaluated.
- The effect of homeopathic medications for respiratory symptoms on the assay performance was not tested.
- BioGX SARS-CoV-2 Reagent and BD MAX TNA-3 extraction have not been evaluated for patients receiving intranasally administered influenza vaccine.

### CONDITIONS OF AUTHORIZATION FOR THE LABORATORY

The BioGX SARS-CoV-2 Reagents for BD MAX System Letter of Authorization, along with the authorized Fact Sheet for Healthcare Providers, the authorized Fact Sheet for Patients, and authorized labeling are available on the FDA website: <https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations>

To assist clinical laboratories running the BioGX SARS-CoV-2 Reagents for BD MAX System, the relevant Conditions of Authorization are listed below, and are required to be met by laboratories performing the EUA test.

- Authorized laboratories\* using the BioGX SARS-CoV-2 Reagents for BD MAX System will include with result reports of the BioGX SARS-CoV-2 for BD MAX System test, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.
- Authorized laboratories using the BioGX SARS-CoV-2 Reagents for BD MAX System will perform the BioGX SARS-CoV-2 Reagents for use with the BD MAX System as outlined in the BioGX SARS-CoV-2 Reagents for BD MAX System Instructions for Use. Deviations from the authorized procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized ancillary reagents, and authorized material required to perform the BioGX SARS-CoV-2 Reagents for BD MAX System test are not permitted.
- Authorized laboratories that receive the BioGX SARS-CoV-2 Reagents for BD MAX System test must notify the relevant public health authorities of their intent to run the test prior to initiating testing.
- Authorized laboratories using the BioGX SARS-CoV-2 Reagents for BD MAX System test will have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.
- All laboratory personnel using the BioGX SARS-CoV-2 Reagents for BD MAX System test must be appropriately trained in RT-PCR techniques and use appropriate laboratory and personal protective equipment when handling this kit, and use the test in accordance with the authorized labeling.
- Becton, Dickinson and Company, authorized distributors, and authorized laboratories using the BioGX SARS-CoV-2 Reagents for BD MAX System will ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

- Authorized laboratories will collect information on the performance of the BioGX SARS-CoV-2 Reagents for BD MAX System test and report to DMD/OHT7-OIR/OPEQ/ CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov) and Becton, Dickinson and Company Customer Technical Support 1.800.638.8663 any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of the BioGX SARS-CoV-2 Reagents for BD MAX System test of which they become aware.

\* For ease of reference, the letter of authorization refers to, "Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate and high complexity tests" as "authorized laboratories".

## NON-CLINICAL PERFORMANCE EVALUATION

### Limit of Detection (LoD)

LoD studies determine the lowest detectable concentration of the SARS-CoV-2 at which approximately 95% of all (true positive) replicates test positive.

To determine the LoD, quantified genomic viral RNA from SARS-CoV-2, obtained from BEI Resources (Cat. No. NR-52285), was serially diluted into pooled negative nasopharyngeal clinical matrix, a total of 5 concentrations levels, with 2-fold serial dilutions between each level. Confirmation of the estimated LoD was performed with one reagent lot in replicates of 20 prepared in pooled nasopharyngeal swab clinical matrix. The LoD is the lowest concentration (reported as genome equivalents/mL, GE/mL) of genomic RNA from SARS-CoV-2 that can be reproducibly distinguished from negative samples  $\geq 95\%$  of the time. The LoD for the assay is 40 GE/mL.

**Table 3. LoD determination using genomic RNA from SARS-CoV-2 USA-WA1/2020 strain**

RNA from strain	Concentration (GE/mL)	Total Valid Results	Positives			Mean Ct.score			
			SARS-CoV-2	N1	N2	N1	RNase P	N2	RNase P
SARS-CoV-2 USA WA1/2020 (Stock 4.8e+07 GE/mL)	40	20	20	20	20	33.8	22.6	34.3	22.7

### Reactivity/ Inclusivity

The nCoV N1 and nCoV N2 primers and probes utilized within the BioGX SARS-CoV-2 Reagents for BD MAX System are identical in sequence to those reported in the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.

An *in silico* comparison of the N1 and N2 primer sets was performed using all 111 available SARS-CoV-2 sequences in the NCBI nt database (Genbank) as of April 1, 2020. Multiple sequence alignment revealed 100% sequence identity (0 mismatches) across the entire 72 base-pair region of the N1 primer/probe set for all sequences. Multiple sequence alignment showed 100% sequence identity (0 mismatches) across the entire 67 base-pair region of the N2 primer/probe set with one exception. Sequence accession MT159720.1 indicates a "T" instead of a "C" at the 5' end of the N2 reverse primer.

In a separate analysis on April 9, 2020, 3,634 full length SARS-Cov-2 genomes were retrieved from the GISAID EpiCoV database, only including human isolates marked as "high coverage". Multiple alignment of the N gene showed that 98.0% of the sequences were a perfect match to the N1 primer set region, and 99.5% were a perfect match to the N2 primer set region.

All variants have a perfect match to either the N1 region or the N2 region primer set.

### Cross-Reactivity

The nCoV N1 and nCoV N2 primers and probes utilized within the BioGX SARS-CoV-2 Reagents for BD MAX System are identical in sequence to those reported in the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. The CDC reported an *in silico* analysis of primer and probe sequences within their IFU (CDC-006-0019, Rev 02), and has been copied below for reference:

BLASTn analysis queries of the 2019-nCoV rRT-PCR assays primers and probes were performed against public domain nucleotide sequences. The database search parameters were as follows: 1) The nucleotide collection consists of GenBank+EMBL+DDBJ+PDB+RefSeq sequences, but excludes EST, STS, GSS, WGS, TSA, patent sequences as well as phase 0, 1, and 2 HTGS sequences and sequences longer than 100Mb; 2) The database is non-redundant. Identical sequences have been merged into one entry, while preserving the accession, GI, title and taxonomy information for each entry; 3) Database was updated on 10/03/2019; 4) The search parameters automatically adjust for short input sequences and the expect threshold is 1000; 5) The match and mismatch scores are 1 and -3, respectively; 6) The penalty to create and extend a gap in an alignment is 5 and 2 respectively.

2019-nCoV\_N1 Assay:

Probe sequence of 2019-nCoV rRT-PCR assay N1 showed high sequence homology with SARS coronavirus and Bat SARS-like coronavirus genome. However, forward and reverse primers showed no sequence homology with SARS coronavirus and Bat SARS-like coronavirus genome. Combining primers and probe, there is no significant homologies with human genome, other coronaviruses or human microflora that would predict potential false positive rRT-PCR results.

#### 2019-nCoV\_N2 Assay:

The forward primer sequence of 2019-nCoV rRT-PCR assay N2 showed high sequence homology to Bat SARS-like coronaviruses. The reverse primer and probe sequences showed no significant homology with human genome, other coronaviruses or human microflora. Combining primers and probe, there is no prediction of potential false positive rRT-PCR results.

In summary, the 2019-nCoV rRT-PCR assay N1 and N2, designed for the specific detection of 2019-nCoV, showed no significant combined homologies with human genome, other coronaviruses, or human microflora that would predict potential false positive rRT-PCR results.

#### CLINICAL EVALUATION

The performance of BioGx SARS-CoV-2 Reagents for BD MAX System with retrospective collected nasopharyngeal swab clinical samples was evaluated using 30 individual negative clinical samples and 30 contrived positive clinical samples collected from patients with signs and symptoms of an upper respiratory infection.

Clinical samples were collected by qualified personnel according to the package insert of the collection device. Samples were handled as described in the package insert of the collection device and stored frozen until use.

Low positive and moderate positive contrived clinical samples were prepared by spiking quantified genomic RNA (SARS-CoV-2 USA-WA1/2020 strain) into individual negative clinical matrix to approximately ~1–2x LoD (20 samples) and ~3–5x LoD (10 samples), respectively.

All low positive and moderate positive samples were positive and all negative samples were negative in the background of individual clinical sample matrix.

**Table 4. Clinical evaluation with contrived nasopharyngeal swab samples**

Sample Concentration	Total Valid Results	Agreement with the expected results	BioGx "N1, RNase P" master mix			BioGx "N2, RNase P" master mix		
			% Positive	Mean Ct.score		% Positive	Mean Ct.score	
				N1	RNase P		N2	RNase P
~1–2x LoD	19/20 <sup>a</sup>	19/19	100 (19/19 <sup>a</sup> )	33.8	23.2	100 (19/19 <sup>a</sup> )	33.7	23.0
~3–5x LoD	10	10/10	100 (10/10)	33.1	21.6	100 (10/10)	33.6	21.4
Negative	30	30/30	0 (N/A)	N/A	22.5	0 (N/A)	N/A	22.3

<sup>a</sup> During screening one retrospective nasopharyngeal swab clinical sample resulted in an UNR for N1 and as a result was removed from data analysis.

#### REFERENCES

1. Clinical and Laboratory Standards Institute. Protection of laboratory workers from occupationally acquired infections; Approved Guideline. Document M29 (Refer to the latest edition).
2. Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in microbiological and biomedical laboratories. Chosewood L.C. and Wilson D.E. (eds) (2009). HHS Publication No. (CDC) 21–1112.
3. BD MAX System User's Manual (refer to the latest revision) BD Life Sciences, Sparks, Maryland 21152 USA.



# Change History

Revision	Date	Change Summary
(02)	2020-03	Formatting correction.
(03)	2020-04	Updates made to reflect FDA authorization. Added additional BD MAX Sample Rack catalog numbers. Clarified Instructions For Use. Updated Result Interpretation, Limit of Detection, and Clinical Evaluation information. Added information on interfering substances. Made typographical edits.
(04)	2020-05	Updated Intended Use and Limitations of the Procedure to include details about nasal and mid-turbinate swabs. Made minor clarifications to MAX System Operation, Quality Control, and Result Interpretation. In Quality Control section the definition of external negative control was changed. Table 1 was updated. Reactivity/Inclusivity was updated.

US Customers only: For symbol glossary, refer to [bd.com/symbols-glossary](https://bd.com/symbols-glossary)



Manufacturer / Производител / Výrobce / Fabrikant / Hersteller / Κατασκευαστής / Fabricante / Tootja / Fabricant / Proizvođač / Gyártó / Fabbicante / Аткарушы / 제조업체 / Gamintojas / Ražotājs / Tilvirker / Producent / Producător / Производитель / Výrobca / Proizvodač / Tilverkare / Üretici / Виробник / 生产厂商



Use by / Используйте до / Spottebujte do / Brug før / Verwendbar bis / Χρήση έως / Usar antes de / Kasutada enne / Date de péremption / 사용 기한 / Upotrijebiti do / Felhasználhatóság dátuma / Usare entro / Дейін пайдалануға / Naudokite iki / Izlietot līdz / Houdbaar tot / Brukes for / Stosować do / Prazo de validade / A se utiliza până la / Исползовать до / Použite do / Upotrebiti do / Använd före / Son kulanma tarihi / Використати до / 使用截止日期  
 YYYY-MM-DD / YYYY-MM (MM = end of month)  
 ГТГГ-ММ-ДД / ГТГГ-ММ (ММ = края на месеца)  
 RRRR-MM-DD / RRRR-MM (MM = koniec miesiąca)  
 AAAA-MM-DD / AAAA-MM (MM = slutning af måned)  
 JJJJ-MM-TT / JJJJ-MM (MM = Monatsende)  
 EEEE-MM-HH / EEEE-MM (MM = τέλος του μήνα)  
 AAAA-MM-DD / AAAA-MM (MM = fin del mes)  
 AAAA-KK-PP / AAAA-KK (KK = kuu lõpp)  
 AAAA-MM-JJ / AAAA-MM (MM = fin du mois)  
 GGGG-MM-DD / GGGG-MM (MM = kraj mjeseca)  
 ÉÉÉÉ-HH-NN / ÉÉÉÉ-HH (HH = hónap utolsó napja)  
 AAAA-MM-GG / AAAA-MM (MM = fine mese)  
 ЖЖЖЖ-АА-КК / ЖЖЖЖ-АА (АА = айдың соңы)  
 YYYY-MM-DD/YYYY-MM (MM = 월말)  
 MMMM-MM-DD / MMMM-MM (MM = mēnesio pabaiga)  
 GGGG-MM-DD/GGGG-MM (MM = mēneša beigas)  
 JJJJ-MM-DD / JJJJ-MM (MM = einde maand)  
 AAAA-MM-DD / AAAA-MM (MM = slutten av måneden)  
 RRRR-MM-DD / RRRR-MM (MM = koniec miesiąca)  
 AAAA-MM-DD / AAAA-MM (MM = fim do mês)  
 AAAA-LL-ZZ / AAAA-LL (LL = sfârșitul lunii)  
 ГТГГ-ММ-ДД / ГТГГ-ММ (ММ = конец месяца)  
 RRRR-MM-DD / RRRR-MM (MM = koniec miesiąca)  
 GGGG-MM-DD / GGGG-MM (MM = kraj meseca)  
 AAAA-MM-DD / AAAA-MM (MM = slutet av månaden)  
 YYYY-AA-GG / YYYY-AA (AA = ayın sonu)  
 PPPP-MM-DD / PPPP-MM (MM = кінець місяця)  
 YYYY-MM-DD / YYYY-MM (MM = 月末)



Catalog number / Каталоген номер / Katalogové číslo / Katalognummer / Αριθμός καταλόγου / Número de catálogo / Katalooginumber / Numéro catalogue / Kataloški broj / Katalógusszám / Numero di catalogo / Каталог номери / 카탈로그 번호 / Katalog / numeris / Kataloga numurs / Catalogus nummer / Numer katalogowy / Număr de catalog / Номер по каталогу / Katalogové číslo / Kataloški broj / Katalog numarası / Номер за каталогом / 目录号



Authorized Representative in the European Community / Оторизирани представител в Европейската общност / Autorizovaný zástupce pro Evropském společenství / Autoriseret repræsentant i De Europæiske Fællesskaber / Autorisierter Vertreter in der Europäischen Gemeinschaft / Εξουσιοδοτημένος αντιπρόσωπος στην Ευρωπαϊκή Κοινότητα / Representante autorizado en la Comunidad Europea / Voittatut esindaja Euroopa Nõukogus / Représentant autorisé pour la Communauté européenne / Autorizirani predstavnik u Evropskoj uniji / Meghatalmazzott képviselő az Európai Közösségekben / Rappresentante autorizzato nella Comunità Europea / Европа қауымдастығындағы уәкілетті өкіл / 유럽 공동체의 위임 대표 / Įgaliotasis atstovas Europos Bendrijoje / Pilnvarotais pārstāvis Eiropas Kopienā / Bevoegde vertegenwoordiger in de Europese Gemeenschap / Autorisert representant i EU / Autoryzowane przedstawicielstwo we Wspólnocie Europejskiej / Representante autorizado na Comunidade Europeia / Reprezentantul autorizat pentru Comunitatea Europeană / Уполномоченный представитель в Европейском сообществе / Autorizovaný zástupca v Európskom spoločenstve / Autorizovano predstavništvo u Evropskoj uniji / Auktoriserad representant i Europeiska gemenskapen / Ανγυρα Τορλuluğu Yetkili Temsilcisi / Уповноважений представник у країнах ЄС / 歐洲共同体授權代表



In Vitro Diagnostic Medical Device / Медицински уред за диагностика ин витро / Lékařské zařízení určené pro diagnostiku in vitro / In vitro diagnostisk medicinsk anordning / Medizinisches In-vitro-Diagnostikum / In vitro διαγνωστική ιατρική συσκευή / Dispositivo médico para diagnóstico in vitro / In vitro diagnostika meditsiiniaparatuur / Dispositif médical de diagnostic in vitro / Medicinska romagala za In Vitro Dijagnostiku / In vitro diagnosztikai orvosi eszköz / Dispositivo medicale per diagnostica in vitro / Жасанды жағдайда жүзрісетін медициналық диагностика аспабы / In Vitro Diagnostic 의료 기기 / In vitro diagnostikos prietaisai / Medicinas ierices, ko lieto in vitro diagnostikā / Medisch hulpmiddel voor in-vitro diagnostiek / In vitro diagnostisk medisinsk utstyr / Urządzenie medyczne do diagnostyki in vitro / Dispositivo médico para diagnóstico in vitro / Dispositiv medical pentru diagnostic in vitro / Медицинский прибор для диагностики ин витро / Medicinska romôcka na diagnostiku in vitro / Medicinski uređaj za in vitro dijagnostiku / Medicinteknik produkt för in vitro-diagnostik / In Vitro Dijagnostik Tibbi Cihaz / Медицинский пристрій для діагностики in vitro / 体外诊断医疗设备



Temperature limitation / Температурни ограничения / Teplotní omezení / Temperaturbegrænsning / Temperaturbegrenzung / Περιορισμοί θερμοκρασίας / Limitación de temperatura / Temperatuuri piirang / Limites de température / Dozvoljena temperatura / Hörmérsékleti határ / Limiti di temperatura / Температураны шектеу / 온도 제한 / Laikymo temperatūra / Temperatūras ierobežojumi / Temperatuurlimiet / Ograniczenie temperatury / Limites de temperatura / Limite de temperatură / Ограничение температуры / Ohraničenie teploty / Ograničenje temperature / Temperaturgräns / Sıcaklık sınırlaması / Обмеження температури / 温度限制



Batch Code (Lot) / Код на партидата / Kód (číslo) šarže / Batch-kode (lot) / Batch-Code (Charge) / Κωδικός παρτίδας (παρτίδα) / Código de lote (lote) / Partii kood / Numéro de lot / Lot (kod) / Tétel száma (lot) / Codice batch (lotto) / Топтама коды / 배치 코드(로트) / Partijos numeris (LOT) / Partijas kods (laidiens) / Lot nummer / Batch-kode (parti) / Kod partii (seria) / Código do lote / Cod de serie (Lot) / Код партии (лот) / Kód série (šarža) / Kod serije / Partinummer (Lot) / Parti Kodu (Lot) / Код партії / 批号 (亚批)



Contains sufficient for <n> tests / Съдържанието е достатъчно за <n> теста / Dostatečné množství pro <n> testů / Indeholder tilstrækkeligt til <n> tests / Ausreichend für <n> Tests / Περιέχει επαρκή ποσότητα για <n> εξετάσεις / Contenido suficiente para <n> pruebas / Küllaldane <n> testide jaoks / Contenu suffisant pour <n> tests / Sadržaj za <n> testova / <n> teszthez elegendő / Contenuto sufficiente per <n> test / <n> тесттери үшін жеткілікті / <n> 테스트가 충분히 포함됨 / Pakankamas kiekis atlikti <n> testų / Satur pietiekami <n> pārbaudēm / Inhoud voldoende voor "n" testen / Innholder tilstrekkelig til <n> tester / Zawiera ilość wystarczającą do <n> testów / Conteúdo suficiente para <n> testes / Conținut suficient pentru <n> teste / Достаточно для <n> тестов(a) / Obsah ystaci(a) na <n> testov / Sadržaj dovoljan za <n> testova / Innehåller tillräckligt för <n> analyser / <n> test için yeterli miktarda içerir / Вистачить для аналізів: <n> / 足够进行 <n> 次检测



Consult Instructions for Use / Направете справка в инструкциите за употреба / Prostudujte pokyny k použití / Se brugsanvisningen / Gebrauchsanweisung beachten / Συμβουλευτείτε τις οδηγίες χρήσης / Consultar las instrucciones de uso / Lugeda kasutusjuhendit / Consulter la notice d'emploi / Koristi upute za upotrebu / Olvassa el a használati utasítást / Consultare le istruzioni per l'uso / Пайдалану нұсқаулығымен танысып алыңыз / 사용 지침 참조 / Skaitykite naudojimo instrukcijas / Skatīt lietošanas pamācību / Raadpleeg de gebruiksaanwijzing / Se i bruksanvisningen / Zobacz instrukcja użytkowania / Consultar as instruções de utilização / Consultați instrucțiunile de utilizare / См. руководство по эксплуатации / Pozri Pokyny na používanie / Pogledajte uputstvo za upotrebu / Se bruksanvisningen / Kullanım Talimatları'na başvurun / Див. інструкції з використання / 请参阅使用说明



Do not reuse / Не използвайте отново / Nepoužívejte opakovaně / Ikke til genbrug / Nicht wiederverwenden / Μην επαναχρησιμοποιείτε / No reutilizar / Mitte kasutada korduvalt / Ne pas réutiliser / Ne koristiti ponovo / Egyszer használatos / Non riutilizzare / Пайдаланбаңыз / 재사용 금지 / Tik vienkartiniam naudojimui / Nelietot atkārtoti / Niet opnieuw gebruiken / Kun til engangsbruk / Nie stosować powtórnie / Não reutilize / Nu refolosiți / Не использовать повторно / Nepoužívejte opakovane / Ne upotrebljavajte ponovo / Får ej återanvändas / Tekrar kullantayın / Не використовувати повторно / 请勿重复使用



Serial number / Серийн номер / Sériové číslo / Seriennummer / Seriennummer / Σειράς αριθμός / N° de serie / Seerianumber / Numéro de série / Serijski broj / Sorozatszám / Numero di serie / Топтамалық нөмірі / 일련 번호 / Serijos numeris / Sērijas numurs / Serie nummer / Numer seryjny / Número de série / Număr de serie / Серийный номер / Seri numarasi / Номер серії / 序列号



For IVD Performance evaluation only / Само за оценка качеството на работа на IVD / Pouze pro vyhodnocení výkonu IVD / Kun til evaluering af IVD ydelse / Nur für IVD-Leistungsbewertungszwecke / Μόνο για αξιολόγηση απόδοσης IVD / Solo para la evaluación del rendimiento en diagnóstico in vitro / Ainult IVD seadme hindamiseks / Réservé à l'évaluation des performances IVD / Samo u znanstvene svrhe za In Vitro Dijagnostiku / Kizárlag in vitro diagnosztikához / Solo per valutazione delle prestazioni IVD / Жасанды жағдайда «пробирка үшін» диагностикада тек жұмысты бағалау үшін / IVD 성능 평가에 대해서만 사용 / Tik IVD prietaisų veikimo charakteristikoms tikrinti / Vienīgi IVD darbības novērtēšanai / Uitsluitend voor doeltreffendheidsonderzoek / Kun for evaluering av IVD-ytelse / Tylko do oceny wydajności IVD / Uso exclusivo para avaliação de IVD / Numai pentru evaluarea performanței IVD / Только для оценки качества диагностики in vitro / Určene iba na diagnostiku in vitro / Samo za procenu učinka u in vitro dijagnostici / Endast för utvärdering av diagnostisk användning in vitro / Yalnızca IVD Performans değerlendirmesi için / Тільки для оцінювання якості діагностики in vitro / 仅限 IVD 性能评估 For US: "For Investigational Use Only"



Lower limit of temperature / Долен лимит на температурата / Dolni hranice teploty / Nedre temperaturgrænse / Temperaturuntergrenze / Κατώτερο όριο θερμοκρασίας / Limite inferior de temperatura / Alumine temperatuuripiiri / Limite inférieure de température / Najnižza dovoljena temperatura / Alsó hőmérsékleti határ / Limite inferiore di temperatura / Температураның төменгі рұқсат шегі / 하한 온도 / Žemiausia laikymo temperatūra / Temperatūras zemākā robeža / Laagste temperatuurlimiet / Nedre temperaturgrænse / Dolna granica temperatury / Limite minimo de temperatura / Limită minimă de temperatură / Limitā maxīmā de temperaturā / Нижний предел температуры / Spodná hranica teploty / Donja granica temperature / Nedre temperaturgräns / Sicaklık alt sınırı / Мінімальна температура / 温度下限



Control / Контроль / Kontrola / Kontrol / Kontrolle / Μάρτυρας / Kontroll / Contrôle / Controllo / Бақылау / 컨트롤 / Kontrolè / Kontrolle / Controle / Controllo / Контроль / kontroll / Контроль / 对照



Positive control / Положителен контрол / Pozitivní kontrola / Positiv kontrol / Positive Kontrolle / Θετικός μάρτυρας / Control positivo / Positiivne kontroll / Contrôle positif / Pozitivna kontrola / Pozitiv kontroll / Controllo positivo / Оң бақылау / 양성 컨트롤 / Teigiama kontrolė / Pozitívá kontrol / Positieve controle / Kontrola dodatnia / Controllo positivo / Control pozitiv / Положительный контроль / Pozitif kontrol / Позитивный контроль / 阳性对照试剂



Negative control / Отрицателен контрол / Negativní kontrola / Negativ kontrol / Negative Kontrolle / Αρνητικός μάρτυρας / Control negativo / Negatiivne kontroll / Contrôle négatif / Negativna kontrola / Negativ kontroll / Controllo negativo / Негативтік бақылау / 음성 컨트롤 / Neigiama kontrolė / Negativá kontrol / Negatieve controle / Kontrola ujemna / Controllo negativo / Control negati / Отрицательный контроль / Negatif kontrol / Негативный контроль / 阴性对照试剂



Method of sterilization: ethylene oxide / Метод на стерилизация: етиленов оксид / Způsob sterilizace: etylenoxid / Steriliseringsmetode: ethylenoxid / Sterilisationsmethode: Ethylenoxid / Μέθοδος αποστείρωσης: αιθυλενοξείδιο / Método de esterilización: óxido de etileno / Steriliseerimismetod: etüleenoksiid / Méthode de stérilisation: oxyde d'éthylène / Metoda sterilizacji: etilen oksid / Sterilizálás módszere: etilén-oxid / Metoda di sterilizzazione: ossido di etilene / Sterilizzazione: ossido di etilene / Sterilization: oxide of ethylene / 소독 방법: 에틸렌 옥사이드 / Sterilizavimo būdas: etileno oksidas / Sterilizēšanas metode: etilēnoksīds / Gesteriliseerd met behulp van ethyleenoxide / Steriliseringsmetode: etylenoksid / Metoda sterylizacji: tielenoksid / Método de esterilização: óxido de etileno / Metoda de sterilizare: oxid de etilenă / Метод стерилизации: этиленоксид / Metoda sterilizácie: etylénoxid / Metoda sterilizacije: etilen oksid / Steriliseringsmetod: etenoxid / Sterilizasyon yöntemi: etilen oksit / Метод стерилизації: етиленоксидом / 灭菌方法: 环氧乙烷



Method of sterilization: irradiation / Метод на стерилизация: ирадиация / Způsob sterilizace: záření / Steriliseringsmetode: bestråling / Sterilisationsmethode: Bestrahlung / Μέθοδος αποστείρωσης: ακτινοβολία / Método de esterilización: irradiación / Steriliseerimismetod: kiirgus / Méthode de stérilisation: irradiation / Metoda sterilizacije: zračenje / Sterilizálás módszere: besugárzás / Metoda di sterilizzazione: irradiazione / Sterilizzazione: raggi / Sterilization: radiation / 소독 방법: 방사 / Sterilizavimo būdas: radiacija / Sterilizēšanas metode: apstarošana / Gesteriliseerd met behulp van bestraling / Steriliseringsmetode: bestraling / Metoda sterylizacji: napromienianie / Método de esterilização: irradiação / Metodă de sterilizare: iradiere / Метод стерилизации: облучение / Metoda sterilizácie: ožiarenie / Metoda sterilizacije: ozračevanje / Steriliseringsmetod: stråling / Sterilizasyon yöntemi: irradyasyon / Метод стерилизації: опроміненням / 灭菌方法: 辐射



Biological Risks / Биологични рискове / Biologická rizika / Biologisk fare / Biogefährdung / Βιολογικοί κίνδυνοι / Riesgos biológicos / Bioloogilised riskid / Risques biologiques / Biološki rizik / Biológiallag veszélyes / Rischio biologico / Биологический тауекелдер / 생물학적 위험 / Biologinis pavojus / Biologiskie riski / Biologisch risico / Biologisk risiko / Zagrożenia biologiczne / Perigo biológico / Riscuri biologice / Биологическая опасность / Biologické riziko / Biološki rizici / Biologisk risk / Biolojisk Riskler / Биологічна небезпека / 生物学风险



Caution, consult accompanying documents / Внимание, направете справка в придружаващите документи / Pozor! Prostudujte si příloženou dokumentaci! / Forsigtig, se ledsagende dokumenter / Achtung, Begleitdokumente beachten / Προσοχή, συμβουλευτείτε τα συνοδευτικά έγγραφα / Precaución, consultar la documentación adjunta / Ettevaatusti! Lugeda kaasnevad dokumentatsioon / Attention, consulter les documents joints / Urozorenje, koristi prateću dokumentaciju / Figyelem! Olvassa el a mellékelt tájékoztatót / Attenzione: consultare la documentazione allegata / Абайлаңыз, тиісті құжаттармен танысыңыз / 주의, 동봉된 설명서 참조 / Dămesio, žiūrėkite pridėdamus dokumentus / Piesardzība, skatīt pavaddokumentus / Voorzichtig, raadpleeg bijgevoegde documenten / Forsiktig, se vedlagt dokumentasjon / Należy zapoznać się z dołączonymi dokumentami / Cuidado, consulte a documentação fornecida / Atenție, consultați documentele însoțitoare / Внимание: см. прилагаемую документацию / Výstraha, pozri sprievodné dokumenty / Pažnja! Pogledajte priložena dokumenta / Obs! Se medföljande dokumentation / Dikkat, birlikte verilen belgelere başvurun / Увага: див. супутню документацию / 小心, 请参阅附带文档。



Upper limit of temperature / Горен лимит на температурата / Horní hranice teploty / Øvre temperaturgrænse / Temperaturobergrenze / Ανώτερο όριο θερμοκρασίας / Limite superior de temperatura / Ülemine temperatuuripiiri / Limite supérieure de température / Gornja dovoljena temperatura / Felső hőmérsékleti határ / Limite superiore di temperatura / Температураның рұқсат етілген жоғарғы шегі / 상한 온도 / Aukščiausia laikymo temperatūra / Augšējā temperatūras robeža / Hoogste temperatuurlimiet / Øvre temperaturgrænse / Górná granica temperatury / Limite máximo de temperatura / Limită maximă de temperatură / Limitā maxīmā de temperaturā / Верхний предел температуры / Horná hranica teploty / Gornja granica temperature / Sicaklık üst sınırı / Максимальна температура / 温度上限



Keep dry / Пазете сухо / Skladujte v suchém prostředí / Orbevares tørt / Trocklagern / Φαλάξτε το στεγνό / Mantener seco / Hoida kuivas / Conserver au sec / Držati na suhom / Száraz helyen tartandó / Tenere all'asciutto / Құрғақ күйінде ұста / 건조 상태 유지 / Laikykite sausai / Uzglabāt sausu / Droog houden / Hoides tørt / Przechowywać w stanie suchym / Manter seco / A se feri de umezeală / Не допускать попадания влаги / Uchovávajte v suchu / Držite na suvom mestu / Förvaras torr / Kuru bir şekilde muhafaza edin / Берегти від вологи / 请保持干燥



Collection time / Време на събиране / Čas odběru / Opsamlingsstidspunkt / Entnahmeuhrzeit / Ώρα συλλογής / Hora de recogida / Kogumisaeg / Heure de prélèvement / Sati prikupljanja / Mintavétel időpontja / Ora di raccolta / Жынау уақыты / 수집 시간 / Paėmimo laikas / Savākšanas laiks / Verzameltijd / Tid prøvetaking / Godzina pobrania / Hora de coleta / Ora colectării / Време сбора / Doba odboru / Vreme prikupljanja / Uppsamlingsstid / Toplama zamanı / Час забору / 采集时间



Peel / Обелете / Otefete zde / Ábn / Abziehen / Αποκολλήστε / Desprender / Koorida / Décoller / Otvoriti skini / Húzza le / Staccare / Үстіңгі қабатын алып таста / 벗기다 / Pliešti cia / Atīmēt / Schillen / Trek av / Oderwać / Destacar / Se dezlipeste / Отклеить / Odtrhnite / Oljušiti / Dra isär / Ayırma / Відклеїти / 撕下



Perforation / Перфорация / Perforace / Perforering / Διείσθηση / Perforación / Perforatsioon / Perforacija / Perforálás / Perforazione / Тесик тесу / 결취선 / Perforacija / Perforácia / Perforatie / Perforacja / Perfuração / Perforare / Перфорация / Perforácia / Perforasyon / Перфорация / 穿孔





Do not use if package damaged / Не използвайте, ако опаковката е повредена / Nepoužívejte, je-li obal poškozený / Må ikke anvendes hvis emballagen er beskadiget / Inhal beschädigter Packung nicht verwenden / Μη χρησιμοποιείτε εάν η συσκευασία έχει υποστεί ζημιώ. / No usar si el paquete está dañado / kui pakend on kahjustatud / Ne pas l'utiliser si l'emballage est endommagé / Ne koristiti ako je oštećeno pakiranje / Ne használja, ha a csomagolás sérült / Non usare se la confezione è danneggiata / Егер пакет бұзылған болса, пайдаланба / पैکیجیگے 손상된 경우 사용 금지 / Jei pakuoatė pažeista, nenaudoti / Nelietot, ja iepakojums bojāts / Niet gebruiken indien de verpakking beschadigd is / Må ikke brukes hvis pakke er skadet / Nie używać, jeśli opakowanie jest uszkodzone / Não usar se a embalagem estiver danificada / A nu se folosi dacă pachetul este deteriorat / Не използovať при повреждении упаковки / Nepoužívať, ak je obal poškodený / Ne koristite ako je pakovanje oštećeno / Använd ej om förpackningen är skadad / Ambalaj hasar görmüşse kullanmayın / Не використовувати за пошкодженої упаковки / 如果包裝破損，請勿使用



Keep away from heat / Пазете от топлина / Nevystavujte přilišnému teplu / Må ikke udsættes for varme / Vor Wärme schützen / Κρατήστε το μακριά από τη θερμότητα / Mantener alejado de fuentes de calor / Hoida eemal valgusest / Protéger de la chaleur / Držati dalje od izvora topline / Óvja a melegtől / Tenere lontano dal calore / Сақын жерде сақта / 열을 피해야 함 / Laikyti atokiau nuo šilumos šaltinių / Sargāt no karstuma / Beschermen tegen warmte / Må ikke utsettes for varme / Przechowywać z dala od źródeł ciepła / Manter ao abrigo do calor / A se feri de căldură / Не нагревать / Uchovávať mimo zdroja tepla / Držite dalje od toplote / Får ej utsättas för värme / Isidan uzak tutun / Беретти від дії тепла / 请远离热源



Cut / Срежете / Odstřihněte / Klip / Schneiden / Κόψτε / Cortar / Lõigata / Découper / Reži / Vágja ki / Tagliare / Keciņa / 잘라내기 / Kirpti / Nogriezt / Knippen / Kutt / Odciać / Cortar / Decupați / Отрезать / Odstrihnite / Iseći / Klipp / Kesme / Розпізати / 剪下



Collection date / Дата на събиране / Datum odběru / Opsamlingsdato / Entnahmedatum / Ημερομηνία συλλογής / Fecha de recogida / Kogumiskuupäev / Date de prélèvement / Dani prikupljanja / Mintavétel dátuma / Data di raccolta / Жинаған тізбекүні / 수집 날짜 / Paëmimo data / Savākšanas datums / Verzameldatum / Dato prøvetaking / Data pobrania / Data de colheita / Data colectării / Дата сбора / Dátum odberu / Datum prikupljanja / Uppsamlingsdatum / Toplama tarihi / Дата забору / 采集日期 / μL/test / μL/тест / μL/Test / μL/εξέταση / μL/prueba / μL/teszt / μL/테스트 / мкл/тест / μL/tyrimas / μL/pārbaude / μL/teste / мкл/анализ / μL/검測



Keep away from light / Пазете от светлина / Nevystavujte světlu / Må ikke udsættes for lys / Vor Licht schützen / Κρατήστε το μακριά από το φως / Mantener alejado de la luz / Hoida eemal valgusest / Conserver à l'abri de la lumière / Držati dalje od svetla / Fény nem érheti / Tenere al riparo dalla luce / Қараңғыланған жерде ұста / 빛을 피해야 함 / Laikyti atokiau nuo šilumos šaltinių / Sargāt no gaismas / Niet blootstellen aan zonlicht / Må ikke utsettes for lys / Przechowywać z dala od źródeł światła / Manter ao abrigo da luz / Feriti de lumină / Хранить в темноте / Uchovávať mimo dosahu svetla / Držite dalje od svetlosti / Får ej utsättas för ljus / Išiktan uzak tutun / Беретти від дії світла / 请远离光线



Hydrogen gas generated / Образуван е водород газ / Možnost úniku plyného vodíku / Frembringer hydrogengas / Wasserstoffgas erzeugt / Δημιουργία αερίου υδρογόνου / Producción de gas de hidrógeno / Vesinikgaasi tekitatud / Produit de l'hydrogène gazeux / Sadrží hydrogen vodík / Hidrogén gázt fejeleszt / Produzione di gas idrogeno / Газтөткөс сүргөй пайда болды / 수소 가스 생성됨 / Išiskiria vandenilio dujas / Rodas ūdeņradis / Waterstofgas gegenereerd / Hydrogengass generert / Powoduje powstawanie wodoru / Produção de gás de hidrogénio / Generare gaz de hidrogen / Выделение водорода / Vyrobené použitím vodíka / Oslobada se vodonik / Genererad välgas / Açığa çıkan hidrojen gazı / Реакция з виділенням водню / 会产生氢气



Patient ID number / ИД номер на пациента / ID pacienta / Patientens ID-nummer / Patienten-ID / Αριθμός αναγνώρισης ασθενούς / Número de ID del paciente / Patsiendi ID / No d'identification du patient / Identifikációs broj pacijenta / Beteg azonosító száma / Numero ID paziente / Пациенттің идентификациялық нөмірі / 환자 ID 번호 / Paciento identifikavimo numeris / Pacienta ID numurs / Identificatienummer van de patiënt / Pasientens ID-nummer / Numer ID pacienta / Número da ID do doente / Numár ID pacient / Идентификационный номер пациента / Identifikačné číslo pacienta / ID broj pacijenta / Patientnummer / Hasta kimlik numarası / Идентификатор пациента / 患者标识号



Fragile, Handle with Care / Чупливо, Работете с необходимото внимание. / Křehké. Při manipulaci postupujte opatrně. / Forsigtig, kan gå i stykker. / Zerbrechlich, vorsichtig handhaben. / Εύθραυστο. Χειριστείτε το με προσοχή. / Frágil. Manipular con cuidado. / Örn, käsitlege ettevaatlikult. / Fragile. Manipuler avec précaution. / Lomljivo, rukujte pažljivo. / Törékeny! Óvatosan kezelendő. / Fragile, maneggiare con cura. / Сыныш, абайлап пайдаланыңыз. / 조심 깨지기 쉬운 처리 / Trapu, eliktis atsargiai. / Trauslis; rikoties uzmanīgi / Breekbaar, voorzichtig behandelen. / Ømtålig, håndter forsigtig. / Krucha zawartość, przenosić ostrożnie. / Frágil, Manuseie com Cuidado. / Frágil, manipulați cu atenție. / Хрупкое! Обращаться с осторожностью. / Křehké, vyžaduje sa opatrná manipulácia. / Lomljivo - rukujte pažljivo. / Bräckligt. Hantera försiktigt. / Kolay Kırılır, Dikkatli Taşıyın. / Тендітна, звертатися з обережністю / 易碎，小心轻放

**R<sub>x</sub> Only** This only applies to US: "Caution: Federal Law restricts this device to sale by or on the order of a licensed practitioner." / S'applique uniquement aux États-Unis: "Caution: Federal Law restricts this device to sale by or on the order of a licensed practitioner." / Vale solo per gli Stati Uniti: "Caution: Federal Law restricts this device to sale by or on the order of a licensed practitioner." / Gilt nur für die USA: "Caution: Federal Law restricts this device to sale by or on the order of a licensed practitioner." / Sólo se aplica a los EE.UU.: "Caution: Federal Law restricts this device to sale by or on the order of a licensed practitioner."

## bd.com/e-labeling

Europe, CH, GB, NO:		+800 135 79 135
International:		+31 20 794 7071
AR	+800 135 79 135	LT 8800 30728
AU	+800 135 79 135	MT +31 20 796 5693
BR	0800 591 1055	NZ +800 135 79 135
CA	+1 855 805 8539	RO 0800 895 084
CO	+800 135 79 135	RU +800 135 79 135
EE	0800 0100567	SG 800 101 3366
GR	00800 161 22015 7799	SK 0800 606 287
HR	0800 804 804	TR 00800 142 064 866
IL	+800 135 79 135	US +1 855 236 0910
IS	800 8996	UY +800 135 79 135
LI	+31 20 796 5692	VN 122 80297



Technical Information: In the United States contact BD Technical Service and Support at 1.800.638.8663 or bd.com.



Becton, Dickinson and Company  
7 Loveton Circle  
Sparks, Maryland 21152 USA

BD, the BD Logo, ExK, and MAX are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners. © 2020 BD. All rights reserved.



## Preparation of External Positive and Negative Controls for BioGX SARS-CoV-2 Reagents for BD MAX™ System

### Purpose

The BioGX SARS-CoV-2 Reagents for BD MAX™ System is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal, nasal, mid-turbinate, and oropharyngeal swab specimens, nasopharyngeal wash/ aspirate or nasal aspirates obtained from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate and high complexity tests.<sup>1</sup>

According to the “Guidance for COVID-19 Testing for CAP-Accredited Laboratories” by the College of American Pathologists, clinical laboratories using EUA assays for COVID-19 testing must perform quality control each of day of patient testing.<sup>2</sup> External positive and negative controls are samples that act as surrogates for clinical specimens. They are processed like a clinical specimen to monitor the ongoing performance of the entire analytic process in every assay run. The purpose of this document is to provide clinical laboratories with suggested procedures for preparing External Positive Controls (EPC) and External Negative Controls (ENC) for the BioGX SARS-CoV-2 Reagents on the BD MAX System using commercially prepared positive controls and materials:

Manufacturer	SARS-CoV-2 Control	Other Control
BioGX SARS-CoV-2 & RNase P Synthetic Single- Stranded RNA Control Templates <sup>3</sup>	SARS-CoV-2 Nucleocapsid Phosphoprotein gene N1 SARS-CoV-2 Nucleocapsid Phosphoprotein gene N2	RNase P
Microbiologics® Helix Elite™ Synthetic RNA Standard <sup>4</sup>	1044 nucleotide segment of SARS-CoV-2 N (nucleocapsid) gene (N1, N2 and N3)	N/A
Integrated DNA Technologies Positive Control Plasmids <sup>5,6</sup>	Complete 2019-nCoV Nucleocapsid gene (N1, N2 and N3)	Portion of the RPP30 single copy gene found in humans

Each suggested procedure for preparing an EPC has been verified by BD. However, the choice of EPC for the BioGX SARS-CoV-2 Reagents for BD MAX System is ultimately the decision of the laboratory, in accordance with applicable local, state, and/or federal regulations, accreditation requirements and the laboratory's standard Quality Control (QC) procedures.

## A) BioGX SARS-CoV-2 Nucleocapsid N1 and N2 genes and RNase P

The BioGX SARS-CoV-2 & RNase P Synthetic Single- Stranded RNA Control Templates kit contains lyophilized control template beads for the SARS-CoV-2 Nucleocapsid Phosphoprotein gene (N1), SARS-CoV-2 Nucleocapsid Phosphoprotein gene (N2), and RNase P.<sup>3</sup> The beads are formulated with quantified RNA (single stranded RNA) at  $1 \times 10^5$  copies per tube in a lyophilized bead format. Each product package contains 1 pouch of 12 tubes with each tube containing 1 lyophilized control template bead.<sup>3</sup> The BioGX SARS-CoV-2 & RNase P Synthetic Single- Stranded RNA Control Templates should be stored at 2-8°C.<sup>3</sup>

**Table 1. Materials Needed for the BioGX External Positive Controls**

Material	Part #
BioGX SARS-CoV-2 & RNase P Synthetic Single- Stranded RNA Control Templates	BD # 444214
BD MAX ExK TNA-3 Sample Buffer Tubes	BD # 442827
Nuclease-free water*	Invitrogen # 4387936**

\*Alternate diluents e.g., Universal Transport Media (UTM) may be used if validated by the laboratory

\*\*or Equivalent

### Preparation of External Positive Controls (EPC) and External Negative Controls (ENC) from BioGX Control Beads

1. To prepare the SARS-CoV-2 N1 and N2 EPC, pipet 650 µL of nuclease-free water into a BD MAX ExK TNA-3 Sample Buffer Tube (SBT).
2. Rehydrate the BioGX SARS-CoV-2 N1 and N2 positive control beads individually with 100 µL of nuclease-free water.
3. Pipette the entire volume of the rehydrated N1 and N2 positive controls into the **same** SBT. Close the SBT with a blue septum cap and vortex or mix by inversion 5 times. Label the SBT as the SARS-CoV-2 N1/N2 EPC.
4. To prepare the RNase P positive control bead, repeat steps 1-3 above with a **new** BD MAX ExK TNA-3 SBT and the BioGX RNase P positive control beads. The rehydrated RNase P positive control bead is added to the separate SBT.
5. Close the SBT with a blue septum cap and vortex or mix by inversion 5 times. Label the tube as the RNase P ENC.
6. Proceed with testing the prepared SARS-CoV-2 N1/N2 EPC SBT and the RNase P ENC SBT with the BioGX SARS-CoV-2 Reagents on BD MAX System according to instructions in the Package Insert.<sup>1</sup>

### Expected Results

Laboratories should refer to the BioGX SARS-CoV-2 Reagents for BD MAX System Package Insert for full interpretation of external control test results.<sup>1</sup> The expected results are below.

Specimens	BioGX "N1, RNase P" mastermix		BioGX "N2, RNase P" mastermix		Result Interpretation
	N1	RNase P	N2	RNase P	
SARS CoV-2 N1/N2 EPC	Pos	Neg	Pos	Neg	Positive
RNase P ENC	Neg	Pos	Neg	Pos	Positive

The SARS CoV-2 N1/N2 EPC and RNase P ENC should yield the expected positive results.

## B) Microbiologics SARS-CoV-2 Synthetic RNA (N gene targets)

The Microbiologics® Helix Elite™ SARS-CoV-2 synthetic RNA standard is a 1044-nucleotide portion of the SARS-CoV-2 N (nucleocapsid) gene containing the three markers N1, N2 and N3. Each kit includes 1 vial of dried synthetic RNA, 1 vial of molecular standard water, and a certificate of analysis.<sup>4</sup> The Helix Elite™ SARS-CoV-2 synthetic RNA standard should be stored at 2-25°C according to the manufacturer's instructions.<sup>4</sup>

**Table 2. Materials Needed for the Microbiologics External Positive Control**

Material	Part #
Microbiologics® Helix Elite™ Synthetic Standard SARS-CoV-2 Synthetic RNA (N gene Targets)	Microbiologics # HE0060S
BD MAX ExK TNA-3 Sample Buffer Tubes	BD # 442827
Molecular standard or Nuclease-free water*	Invitrogen # 4387936**
1X TE buffer, pH 8.0	Thermo Fisher Scientific # AM9849**
2 mL Tubes	VWR # 10025-756**

\*Alternate diluents e.g., Universal Transport Media (UTM) may be used if validated by the laboratory

\*\*or Equivalent

### Preparation of External Positive Control from Microbiologics Standard

1. To prepare the SARS-CoV-2 Synthetic RNA EPC, add 750 µL of nuclease-free water into a BD MAX ExK TNA-3 Sample Buffer Tube (SBT).
2. Rehydrate the lyophilized powder of the Helix Elite™ SARS-CoV-2 Synthetic RNA standard and dilute per the manufacturer's instructions.<sup>4</sup>
  - a. Add 55 µL of nuclease-free water for a concentration stock.
  - b. Dilute the rehydrated SARS-CoV-2 Synthetic RNA by transferring 90 µL of nuclease-free water to 10 µL of the concentrated stock.
3. Prepare the spiking dilution by adding 94.5 µL of nuclease-free water to 5.5 µL of the diluted stock.
4. Pipette 50 µL of the diluted stock into the SBT.
5. Close the SBT with a blue septum cap and vortex or mix by inversion 5 times. Label the SBT as the SARS-CoV-2 Synthetic RNA EPC.
6. Proceed with testing the prepared SARS-CoV-2 Synthetic RNA EPC SBT with the BioGX SARS-CoV-2 Reagents on BD MAX System according to instructions in the Package Insert.<sup>1</sup>

### Expected Results

Laboratories should refer to the BioGX SARS-CoV-2 Reagents for BD MAX System Package Insert for full interpretation of external control test results.<sup>1</sup> The expected results are below.

Specimens	BioGX "N1, RNase P" mastermix		BioGX "N2, RNase P" mastermix		Result Interpretation
	N1	RNase P	N2	RNase P	
SARS-CoV-2 Synthetic RNA EPC	Pos	Neg	Pos	Neg	Positive

The SARS-CoV-2 Synthetic RNA EPC should yield the expected positive results.

### C) IDT 2019-nCoV\_N and Hs\_RPP30 Positive Control Plasmids

The Integrated DNA Technologies (IDT) 2019-nCoV\_N Positive Control plasmid contains the complete nucleocapsid gene from 2019-nCoV (SARS-CoV-2). The Hs\_RPP30 Positive Control plasmid contains a portion of the RPP30 gene, a single copy gene present in the human genome.<sup>5,6</sup> The IDT control plasmids are derived from the CDC nCoV EUA kit. Control Plasmids are delivered at 250 µL (200,000 copies/µL) in IDTE, pH 8.0. Store at -20°C or colder.

**Table 3. Materials Needed for the IDT External Positive Controls**

Material	Part #
IDT 2019-nCoV_N_Positive Control Plasmid	IDT # 10006625
IDT Hs_RPP30 Positive Control Plasmid	IDT # 10006626
ExK TNA-3 Sample Buffer Tubes	BD # 442827
Nuclease-free water*	Invitrogen # 4387936**
1X TE, buffer pH 8.0	Thermo Fisher Scientific # AM9849**
2 mL Tubes	VWR # 10025-756**

\*Alternate diluents e.g., Universal Transport Media (UTM) may be used if validated by the laboratory

\*\*or Equivalent

### Preparation of External Positive Controls (EPC) and External Negative Controls (ENC) from IDT Control Plasmids

1. To prepare the 2019-nCoV\_N EPC add 750 µL of nuclease-free water into a BD MAX ExK TNA-3 Sample Buffer Tube (SBT).
2. Prepare a dilution of the stock IDT 2019-nCoV\_N Positive Control plasmid (200,000 copies/µL) in TE buffer (See Table 4 for dilution scheme).
3. Pipette 50 µL of the 200 copies/µL diluted stock into the SBT.
4. Close the SBT with a blue septum cap and vortex or mix by inversion 5 times. Label the SBT as the 2019-nCoV\_N EPC.
5. To prepare the Hs\_RPP30 EPC, repeat steps 1-3 above with a **new** BD MAX ExK TNA-3 SBT and the IDT Hs\_RPP30 Positive Control Plasmid.
6. Close the SBT with a blue septum cap and vortex or mix by inversion 5 times. Label the SBT as the Hs\_RPP30 ENC.
7. Proceed with testing the 2019-nCoV\_N EPC SBT and the Hs\_RPP30 ENC SBT with the BioGX SARS-CoV-2 Reagents on BD MAX System according to instructions in the Package Insert.<sup>1</sup>

**Table 4. IDT 2019-nCoV\_N and Hs\_RPP30 Plasmid Dilution Scheme**

Stock (cps/µL)	Dilution Factor	Total Volume of Buffer (µL)	Volume of Stock to Spike (µL)	Volume of TE buffer (µL)	Dilution Conc (cps/µL)
200,000	10	50	5	45	20,000
20,000	10	100	10	90	2,000
2,000	10	500	50	450	200

## Expected Results

Laboratories should refer to the BioGX SARS-CoV-2 Reagents for BD MAX System Package Insert for full interpretation of external control test results.<sup>1</sup> The expected results are below.

Specimens	BioGX “N1, RNase P” mastermix		BioGX “N2, RNase P” mastermix		Result Interpretation
	N1	RNase P	N2	RNase P	
2019-nCoV_N EPC	Pos	Neg	Pos	Neg	Positive
Hs_RPP30 ENC	Neg	Pos	Neg	Pos	Positive

*The 2019-nCoV\_N EPC and Hs\_RPP30 ENC should yield the expected positive results.*

## Expanding the Protocols

The example protocols described above may be expanded at the laboratory’s discretion by increasing the number of each EPC for each run of the BioGX SARS-CoV-2 Reagents for BD MAX System. Please follow the Storage and Stability instructions in the respective Package Inserts of all media and materials used.

**IMPORTANT NOTE:** Laboratories should follow Good Laboratory Practices and Universal Precautions at all times during preparation and use of external control materials. All materials should be disposed of properly as required by the institution.

## Technical Service and Support

BD is committed to providing our customers timely and accurate support. If there are any questions or concerns about this document or the contents, please contact BD Life Sciences – Integrated Diagnostic Solutions Technical Service and Support by dialing 1-800-638-8663 (US).

## References

- (1) BioGX SARS-CoV-2 Reagents for BD MAX™ System Package Insert. Becton Dickinson and Company, Sparks, MD. (Latest version).
- (2) College of American Pathologists “Guidance for COVID-19 Testing for CAP-Accredited Laboratories”  
<https://www.cap.org/laboratory-improvement/news-and-updates/guidance-for-covid-19-testing-for-cap-accredited-laboratories>  
Accessed March 21, 2020.
- (3) BioGX SARS-CoV-2 & RNase P Synthetic Single- Stranded RNA Control Templates. Package Insert (Latest version)
- (4) Microbiology® Helix Elite™ Synthetic Standard SARS-CoV-2 Synthetic RNA (N Gene Targets). Package Insert (Latest version)
- (5) Integrated DNA Technologies 2019-nCoV\_N\_Positive Control Plasmid. Product Description (Latest version)
- (6) Integrated DNA Technologies Hs\_RPP30 Positive Control Plasmid. Product Description (Latest version)

BD, Sparks, MD 21152-0999 USA  
Tel: 800.638.8663

**bd.com**



BD, the BD Logo, ExK and MAX are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners. © 2020 BD. All rights reserved.